Shopping Cart
- Remove All
- Your shopping cart is currently empty
Osocimab (BAY 1213790) is a potent anti-FXIa antibody with a Ki value of 2.4 nM and an EC50 value of 0.2 nM.Osocimab may reduce thrombosis through FXI inhibition.Osocimab is often used as an XI factor inhibitor, has an inhibitory effect on thrombin generation, has an anticoagulant effect, and is used in the study of thromboembolic diseases. Thromboembolic Diseases
Pack Size | Price | Availability | Quantity |
---|---|---|---|
1 mg | $247 | In Stock | |
5 mg | $647 | In Stock | |
10 mg | $987 | In Stock |
Description | Osocimab (BAY 1213790) is a potent anti-FXIa antibody with a Ki value of 2.4 nM and an EC50 value of 0.2 nM.Osocimab may reduce thrombosis through FXI inhibition.Osocimab is often used as an XI factor inhibitor, has an inhibitory effect on thrombin generation, has an anticoagulant effect, and is used in the study of thromboembolic diseases. Thromboembolic Diseases |
Targets&IC50 | FIX activation:16 nM, Substrate cleavage (FXIa mediated):1.2 nM |
In vitro | In human plasma, Osocimab (1.4 nM-1 μM; 30 min) demonstrated inhibition of thrombin production, as well as FXIa-mediated FIX activation (or FIX conversion) with an IC50 of 16 nM and FXIa-mediated substrate cleavage with an IC50 of 1.2 nM [1]. Osocimab, at a concentration of 22.05 mg/mL, inhibited activation of the intrinsic pathway-mediated coagulation cascade [1]. |
Alias | BAY 1213790 |
Molecular Weight | 144.46 kDa |
Cas No. | 2056878-75-0 |
Storage | store at low temperature | store at -80°C | Shipping with blue ice. |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.